Valuation: HBM Holdings Limited

Market Cap 932M 7.31B 849M 782M 712M 1.34B 86.33B 1.4B 9.52B 3.78B 47.15B 3.5B 3.42B 148B P/E 2026 *
11.3x
P/E 2027 * 9.93x
Enterprise Value 932M 7.31B 849M 782M 712M 1.34B 86.33B 1.4B 9.52B 3.78B 47.15B 3.5B 3.42B 148B EV / Sales 2026 *
4.31x
EV / Sales 2027 * 4.18x
Free-Float
77.21%
Yield 2026 *
-
Yield 2027 * -
1 day-10.24%
1 week-16.03%
Current month-9.28%
1 month-15.39%
3 months-45.71%
6 months-24.94%
Current year-27.22%
1 week 8.72
Extreme 8.715
10.61
1 month 8.72
Extreme 8.715
11.33
Current year 8.72
Extreme 8.715
17.07
1 year 8.72
Extreme 8.715
17.07
3 years 1.01
Extreme 1.01
17.98
5 years 0.87
Extreme 0.87
17.98
10 years 0.87
Extreme 0.87
17.98
Manager TitleAgeSince
Chief Executive Officer 62 2016-07-19
President - 2026-04-15
Director of Finance/CFO 37 2025-04-08
Director TitleAgeSince
Chairman 62 2016-07-19
Director/Board Member 81 2016-11-30
Director/Board Member 63 2020-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
5/11/26 Other

Director

12,850 0.0014%
12/31/23 Other

Chief Technology Officer

136,000 0.0177%
12/31/23 Other 1,201,000 0.1563%
Change 5-day change 1-year change 3-year change Capi.($)
-10.24%-16.03%-37.23%+433.13% 932M
-0.30%-6.68%+29.12%+125.42% 1,200B
+1.25%-5.35%+33.19%+80.42% 651B
+0.94%-2.99%+24.73%+106.93% 506B
-0.60%-1.95%+27.26%+67.32% 377B
+0.69%-9.50%+40.80%+30.23% 330B
+0.41%-4.70%+27.23%+51.59% 288B
+0.81%-4.08%-1.74%+32.71% 272B
-0.15%-6.45%+29.63%+64.18% 236B
-0.06%-0.98%+33.15%+118.99% 206B
Average -0.69%-5.88%+20.61%+111.09% 407B
Weighted average by Cap. +0.40%-5.19%+28.02%+87.57%

Financials

2026 *2027 *
Net sales 216M 1.69B 197M 181M 165M 310M 20.02B 325M 2.21B 878M 10.93B 811M 794M 34.32B 223M 1.75B 203M 187M 170M 320M 20.67B 336M 2.28B 906M 11.29B 838M 820M 35.44B
Net income 90.65M 710M 82.56M 76.08M 69.2M 130M 8.39B 136M 926M 368M 4.58B 340M 333M 14.39B 102M 796M 92.56M 85.29M 77.58M 146M 9.41B 153M 1.04B 413M 5.14B 381M 373M 16.13B
Net Debt - -
Projected Income Statement - Annual - HBM Holdings Limited
Logo HBM Holdings Limited
Hbm Holdings Ltd is an investment holding company primarily engaged in the business of developing innovative therapeutics in the fields of immuno-oncology and immunology diseases. The Company’s products primarily include BATOCLIMAB (HBM9161), HBM9378, HBM7020, TCE Program, PORUSTOBART (HBM4003), HBM7022 and others. The products are primarily used to treat generalized myasthenia gravis (gMG), chronic obstructive pulmonary disease (COPD), asthma, autoimmune diseases, melanoma, colorectal carcinoma (CRC) and solid tumors. The Company provides next-generation antibody and biotherapeutic solutions through proprietary antibody technology platforms including Harbour Mice, HBICE, HBICA and single B cell cloning platform.
Employees
327
Date Price Change Volume
26-11-20 HK$8.850 -10.24% 10,599,303
26-11-19 HK$9.860 -2.18% 3,833,611
26-11-18 HK$10.08 -0.20% 6,481,000
26-11-17 HK$10.10 -1.37% 3,742,536
26-11-16 HK$10.24 -2.85% 5,103,000
Trader
Investor
-
Global
-
Quality
ESG MSCI
A
MarketScreener Ratings - HBM Holdings Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.129USD
Average target price
3.062USD
Spread / Average Target
+171.15%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - HBM Holdings Limited
  1. Stock Market
  2. Stocks
  3. 2142 Stock